Introduction
Although the current treatment strategy (wait-and-watch strategy) for type B intramural hematoma (IMHB) is in line with the management of type B dissection, the long-term outcomes of IMHB are not as good as those of type B dissection [1-4] . The cause of this phenomenon is that the evolution of IMHB is highly unpredictable and can vary from complete resolution to abrupt rupture. Schoenhoff et al.[5] reported that 43% of IMHB patients underwent thoracic endovascular aortic repair (TEVAR) during the first two weeks because of visualization of an entry tear and development of an aneurysm, and 19% of patients received TEVAR after the acute phase and during the first year. Durham and colleagues also reported that the survival rate of IMHB patients who underwent interventional treatment was only 76%, and only 40% of patients did not require reintervention